TNXP Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

3.23M

+24.9%

-2.915

-70.16%

21.90M

+801.61%

-3.160

+11.27%

37.10M

+1756.86%

-2.730

-29.27%

Estimates Revision

The market is revising Upward the revenue expectations for Tonix Pharmaceuticals Holding Corp. (TNXP) for FY2025, with the revenue forecasts being adjusted by 19.45% over the past three months. During the same period, the stock price has changed by -31.35%.

Revenue Estimates for FY2025

Revise Upward

+19.45%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-10.01%

In Past 3 Month

Stock Price

Go Down

-31.35%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Tonix Pharmaceuticals Holding Corp (TNXP.O) is -1.74, compared to its 5-year average forward P/E of -1.31. For a more detailed relative valuation and DCF analysis to assess Tonix Pharmaceuticals Holding Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.31

Current PE

-1.74

Overvalued PE

0.18

Undervalued PE

-2.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.99

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

5.74

Undervalued EV/EBITDA

-9.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.65

Current PS

1.90

Overvalued PS

4.12

Undervalued PS

-0.83

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TNXP News & Events

Events Timeline

No data

News

5.0

12-09Globenewswire

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel to Enhance Product Commercialization

5.0

12-09Newsfilter

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel to Enhance Product Commercialization

9.0

11-24Newsfilter

Tonix Receives FDA Clearance for Phase 2 Study of TNX-102 SL in Major Depressive Disorder

People Also Watch

Frequently Asked Questions

What is Tonix Pharmaceuticals Holding Corp (TNXP) stock price today?

The current price of TNXP is 19.05 USD — it has decreased -1.19 % in the last trading day.

What is Tonix Pharmaceuticals Holding Corp (TNXP)'s business?

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.

What is the price predicton of TNXP Stock?

Wall Street analysts forecast TNXP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNXP is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Tonix Pharmaceuticals Holding Corp (TNXP)'s revenue for the last quarter?

Tonix Pharmaceuticals Holding Corp revenue for the last quarter amounts to 3.29M USD, increased 16.58 % YoY.

What is Tonix Pharmaceuticals Holding Corp (TNXP)'s earnings per share (EPS) for the last quarter?

Tonix Pharmaceuticals Holding Corp. EPS for the last quarter amounts to -3.59 USD, decreased -84.31 % YoY.

What changes have occurred in the market's expectations for Tonix Pharmaceuticals Holding Corp (TNXP)'s fundamentals?

How many employees does Tonix Pharmaceuticals Holding Corp (TNXP). have?

Tonix Pharmaceuticals Holding Corp (TNXP) has 81 emplpoyees as of December 15 2025.

What is Tonix Pharmaceuticals Holding Corp (TNXP) market cap?

Today TNXP has the market capitalization of 227.05M USD.